Trade Names:Altabax- Ointment 10 mg/g
Selectively inhibits bacterial protein synthesis, inhibiting peptidyl transfer, blocking P-site interactions, and preventing normal formation of active 50S ribosomal subunits.
Systemic exposure after topical application to intact and debrided skin is low. Following twice-daily topical application, 11% of patients had measurable retapamulin concentrations with a median concentration of 0.8 ng/mL.
Protein binding is approximately 94%.
In vitro studies indicate that CYP3A4 is the major enzyme responsible for the metabolism of retapamulin to numerous metabolites.
Topical treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes .
Topical Apply a thin layer to affected area (up to 100 cm 2 in total area) twice daily for 5 days.Children 9 mo of age and older
Topical Apply a thin layer to affected area (or 2% of total body surface area) twice daily for 5 days.
Store at 59° to 86°F.
Retapamulin plasma levels may be increased; however, dosage adjustments are unnecessary.
None well documented.
Pruritus (2%); eczema (1%).
Diarrhea (2%); nausea (1%).
Application-site irritation (2%).
Category B .
Safety and efficacy not established in children younger than 9 months of age.
May promote overgrowth of nonsusceptible microorganisms.
If sensitization or severe local irritation occurs, discontinue use and wipe off ointment.
Not intended for ingestion or oral, intranasal, ophthalmic, or intravaginal use, or for use on mucosal surfaces.
Has not been reported.
Copyright © 2009 Wolters Kluwer Health.